Posted by Michael Wonder on 10 Jun 2020
Cardiff Oncology announces expanded access program for onvansertib in KRAS mutated metastatic colorectal cancer as follow-on to fast track designation
9 June 2020 - Expanded Access Program provides pathway for patients to gain access to treatment with onvansertib outside of clinical trials.
Cardiff Oncology today announced initiation of its Expanded Access Program for its investigational drug onvansertib, in combination with standard-of-care FOLFIRI and bevacizumab, for second-line treatment of patients with KRAS-mutated metastatic colorectal cancer.
The Expanded Access Program (or compassionate use) is a program recognised by the FDA as a follow-on to their granting fast track designation to onvansertib.
